Because ICIs directed against PD-1 and CTLA4 are highly effective in dMMR/MSI-H CRCs, and CTLA4 blockade reduces immature myeloid cells in cancers38, blockade of the CTLA4 axis may be appropriate for MSI-H CRC patients with inflammatory conditions. The gene discussed is CTLA4; the disease is colorectal carcinoma.